高敏肌钙蛋白I浓度与疑似急性冠脉综合征患者心脏结局的关联
结果显示该阈值对主要结局的阴性预测值为99.5%(95%CI 99.3%-99.6%),对30天心源性死亡的阴性预测值为99.9%(95%CI 99.7%-99.9%)。
要点
- 就诊时高敏肌钙蛋白I低于5 ng/L者占49%,30天心肌梗死或心源性死亡阴性预测值99.5%。
- 该阈值下30天无死亡,1年内心源性死亡7例(0.1%),阴性预测值99.9%。
- 仍需进一步研究该风险分层方法的临床效用与成本效益。
核心结论
- 在疑似急性冠脉综合征患者中,高敏肌钙蛋白I低于5 ng/L可识别30天心肌梗死或心源性死亡低风险者。
研究设计与样本
- 系统检索MEDLINE、EMBASE、Cochrane和Web of Science(2006年1月1日至2017年3月18日)的前瞻性研究。
- 纳入19个队列,其中17个队列获取个体患者数据、2个队列使用汇总数据。
主要发现
- 主要结局(30天心肌梗死或心源性死亡)发生于2786例(12.4%)。
- 该阈值对主要结局的阴性预测值为99.5%(95%CI 99.3%-99.6%),对30天心源性死亡的阴性预测值为99.9%(95%CI 99.7%-99.9%)。
- 低于5 ng/L者1年内心源性死亡7例(0.1%)。
关键数值与推荐
- 高敏肌钙蛋白I低于5 ng/L作为就诊时风险分层阈值,主要结局阴性预测值99.5%(95%CI 99.3%-99.6%)。
- 30天心源性死亡阴性预测值99.9%(95%CI 99.7%-99.9%)。
临床怎么用
- 对疑似急性冠脉综合征患者,就诊时高敏肌钙蛋白I低于5 ng/L可识别30天心肌梗死或心源性死亡低风险者。
- 原文指出需进一步研究该风险分层方法的临床效用与成本效益。
局限性
- 原文未述局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: High-sensitivity cardiac troponin I testing is widely used to evaluate patients with suspected acute coronary syndrome. A cardiac troponin concentration of less than 5 ng/L identifies patients at presentation as low risk, but the optimal threshold is uncertain. OBJECTIVE: To evaluate the performance of a cardiac troponin I threshold of 5 ng/L at presentation as a risk stratification tool in patients with suspected acute coronary syndrome. DATA SOURCES: Systematic search of MEDLINE, EMBASE, Cochrane, and Web of Science databases from January 1, 2006, to March 18, 2017. STUDY SELECTION: Prospective studies measuring high-sensitivity cardiac troponin I concentrations in patients with suspected acute coronary syndrome in which the diagnosis was adjudicated according to the universal definition of myocardial infarction. DATA EXTRACTION AND SYNTHESIS: The systematic review identified 19 cohorts. Individual patient-level data were obtained from the corresponding authors of 17 cohorts, with aggregate data from 2 cohorts. Meta-estimates for primary and secondary outcomes were derived using a binomial-normal random-effects model. MAIN OUTCOMES AND MEASURES: The primary outcome was myocardial infarction or cardiac death at 30 days. Performance was evaluated in subgroups and across a range of troponin concentrations (2-16 ng/L) using individual patient data. RESULTS: Of 11 845 articles identified, 104 underwent full-text review, and 19 cohorts from 9 countries were included. Among 22 457 patients included in the meta-analysis (mean age, 62 [SD, 15.5] years; n = 9329 women [41.5%]), the primary outcome occurred in 2786 (12.4%). Cardiac troponin I concentrations were less than 5 ng/L at presentation in 11 012 patients (49%), in whom there were 60 missed index or 30-day events (59 index myocardial infarctions, 1 myocardial infarction at 30 days, and no cardiac deaths at 30 days). This resulted in a negative predictive value of 99.5% (95% CI, 99.3%-99.6%) for the primary outcome. There were no cardiac deaths at 30 days and 7 (0.1%) at 1 year, with a negative predictive value of 99.9% (95% CI, 99.7%-99.9%) for cardiac death. CONCLUSIONS AND RELEVANCE: Among patients with suspected acute coronary syndrome, a high-sensitivity cardiac troponin I concentration of less than 5 ng/L identified those at low risk of myocardial infarction or cardiac death within 30 days. Further research is needed to understand the clinical utility and cost-effectiveness of this approach to risk stratification.
引用
- Chapman AR, Lee KK, McAllister DA, et al. Association of High-Sensitivity Cardiac Troponin I Concentration With Cardiac Outcomes in Patients With Suspected Acute Coronary Syndrome. JAMA. 2017. PMID: 29127948. doi:10.1001/jama.2017.17488
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。